Tag Archives: investing
A Star-Spangled April For Moats
Performance Overview Moat-rated companies continued their strong start to 2016 in April. U.S.-oriented Morningstar® Wide Moat Focus IndexSM (MWMFTR) topped the S&P 500® Index (5.20% vs. 0.39%) in April and widened the gap in relative performance year-to-date (12.05% vs. 1.74%). On the international front, Morningstar® Global ex-US Moat Focus IndexSM (MGEUMFUN) lagged the MSCI All Country World Index ex USA in April (1.43% vs. 2.63%), but maintained relative outperformance year-to-date (4.09% vs. 2.25%). U.S. Domestic Moats: Healthcare Rotation Pays Off St. Jude Medical, Inc. (NYSE: STJ ) was the big winner among domestic moat-rated companies in April. Late in the month Abbott Laboratories (NYSE: ABT ) announced its intent to buy STJ US in a deal that is expected to close in the coming fourth quarter. As part of its quarterly review, the MWMFTR Index rotated into several healthcare companies, including STJ. According to Morningstar, the healthcare sector offered a number of attractive valuation opportunities in March, some of which contributed to MWMFTR’s strong performance in April. Drug manufacturer Allergan plc (NYSE: AGN ), however, provided no such boost to results. A U.S. Department of Treasury tax ruling squashed any hope for its planned merger with Pfizer (NYSE: PFE ), pushing AGN lower for the month. International Moats: Oh, Canada MGEUMFUN’s exposure to financials companies, particularly Canadian banks, contributed to positive performance in April. Only three of the 24 financials companies in the Index posted negative returns last month. Additionally, Russian operator Mobile Telesystems (NYSE: MBT ) has been on a roll since announcing solid fourth quarter results in March. Strains on performance came largely from some of the Index’s consumer discretionary constituents, such as Macau gaming firm Sands China ( OTCPK:SCHYY ) and Chinese car manufacturer Dongfeng Motor Group Co. ( OTCPK:DNFGY ). Monthly Index Total Returns Top/Bottom Index Performers Index Reconstitution Editor’s Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.
Taking Profits On Our SPY Call Spread
You have just made a respectable 10.40% profit in only two trading days. What’s more, you have captured 90.32% of the maximum potential profit in this position. So it’s time to take a welcome profit. The risk/reward of running this position into the May 20 expiration is no longer favorable. As I argued vociferously at the February 11 bottom, yield support is underpinning stocks in a huge way, frustrating the hell out of short sellers, market timers, and hedge funds everywhere. With the volatility Index (VIX) plunging to the $13 handle today we have a nice opportunity to sell the S&P 500 SPDR’s (NYSEARCA: SPY ) May , 2016 $195-$198 in-the-money vertical bull call spread for a few extra pennies than we could yesterday. This all lends further credibility to my “Dreaded Flat Line of Death Scenario” whereby markets move sideways in a narrow range and nobody makes any money, except us. To see how to enter this trade in your online platform, please look at the order ticket below, which I pulled off of optionshouse . The best execution can be had by placing your bid for the entire spread in the middle market and waiting for the market to come to you. The difference between the bid and the offer on these deep in-the-money spread trades can be enormous. Don’t execute the legs individually or you will end up losing much of your profit. Spread pricing can be very volatile on expiration months farther out. Here are the specific trades you need to execute this position: Sell 37 May, 2016 $195 calls at………….….……$12.40 Buy to cover short 37 May, 2016 $198 calls at…..$9.43 Net Cost:…………………………………………………..$2.97 Profit: $2.97 – $2.69 = $0.28 (37 X 100 X $0.28) = $1,036 or 10.40% profit in 2 trading days. Is That a Profit I See? Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.